Heidi Anne Duerr, MPH

Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Prepare your patients for the Fourth of July with expert tips from Roger Rivera, FNP, PMHNP, DNP, on managing risky behaviors, adherence distractions, PTSD-related triggers, and sensory overload during the holiday.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.

Judith Joseph, MD, MBA, shares her journey of balancing clinical work with social media mental health advocacy.

Additionally, 27% of US adults have reported they have a disability across a spectrum of areas.

Recent research found approximately 60 documented cases of suicidal ideation and 7 suicide attempts associated with semaglutide use in patients.

The psilocybin did well on safety and efficacy in this phase 2 trial of patients with PTSD.

Sudhakar K. Shenoy, MD, discusses annual meeting, hot topics in child and adolescent psychiatry, and other issues in psychiatry.

Laura T. Safar, MD, led a discussion on the prevalence and prevention of violence in the workplace.

Poster aims to improve awareness of the potential risk of suicidal ideation in patients taking semaglutide.

Poster at the 2024 APA Annual Meeting explores link between MDD, atopic dermatitis, psoriasis, and inflammation.

Speakers at the APA Annual Meeting share insights regarding to disability, both in patients and in clinicians.

The new formulation was approved to help patients with tardive dyskinesia who have trouble swallowing.

A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.

In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.

In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.

Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.

2023 World AIDS Day looks to remember those who have been lost and a renewed commitment to supporting patients with HIV/AIDS.

What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.

What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.